Celcuity’s (CELC) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report sent to investors on Thursday, MarketBeat.com reports. They currently have a $122.00 price objective on the stock.

A number of other brokerages also recently commented on CELC. Jefferies Financial Group boosted their price objective on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Wells Fargo & Company began coverage on Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. Finally, Wolfe Research reissued an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

Celcuity Price Performance

CELC opened at $114.81 on Thursday. The company has a market capitalization of $5.31 billion, a price-to-earnings ratio of -30.29 and a beta of 0.38. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity has a 12-month low of $7.57 and a 12-month high of $120.32. The business’s fifty day simple moving average is $109.51 and its 200-day simple moving average is $90.44.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. On average, equities research analysts anticipate that Celcuity will post -2.62 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 15.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CELC. Creative Planning acquired a new stake in Celcuity in the second quarter worth about $177,000. Intech Investment Management LLC increased its holdings in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after acquiring an additional 734 shares in the last quarter. Rhumbline Advisers raised its position in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Celcuity in the 2nd quarter valued at approximately $169,000. Finally, Saturn V Capital Management LP boosted its stake in Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after purchasing an additional 91,843 shares in the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $125 and maintained a “buy” rating, signaling increased analyst confidence and providing fresh upside for investors. Article Title
• Positive Sentiment: Needham & Company reaffirmed its “buy” rating and a $122 price target, reinforcing the broker-dealer support that can sustain upward momentum. Benzinga Street Insider
• Positive Sentiment: Q4 2025 results beat estimates: EPS of ($0.73) vs. consensus ($1.06) — the miss narrowed and the beat reduces near-term downside from earnings concerns. Market commentary and the company release came with the results. MarketBeat Earnings
• Positive Sentiment: Management highlighted a potential ~$2.5B annual peak revenue opportunity for gedatolisib and ongoing pivotal milestones/commercial launch preparations — a high commercial upside that supports premium valuations if regulatory and launch execution succeed. MSN Article
• Neutral Sentiment: Investors can review the full Q4 call transcript and highlights for more color on development timelines, cash runway and next catalysts (transcript and call recording available). Seeking Alpha Transcript Yahoo Highlights
• Neutral Sentiment: Corporate release summarizing Q4 and full-year 2025 results and the company update (official details on financials and program status). GlobeNewswire
• Positive Sentiment: Press coverage noting that Celcuity’s breast cancer drug is approaching regulatory milestones/possible approval has likely boosted optimism around near-term value realization. Investing.com
• Negative Sentiment: Company remains unprofitable (negative EPS) and carries leverage (reported debt-to-equity and negative PE), risks that could limit gains if clinical or regulatory setbacks occur. Press Release PDF

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.